Skip to main content
Novacyt logo

Novacyt — Investor Relations & Filings

Ticker · ALNOV ISIN · FR0010397232 LEI · 213800BWAC2BF295EG28 PA Manufacturing
Open in API
Filings indexed 1,101 across all filing types
Latest filing 2026-01-21 Earnings Release
Country FR France
Listing PA ALNOV

About Novacyt

https://novacyt.com/

Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services. The company's core activities include the design, development, manufacturing, and commercialization of in vitro and molecular diagnostic tests, with a specialization in real-time PCR (qPCR) kits and reagents. Novacyt's solutions are applied across various markets, including clinical diagnostics for human health, with a focus on infectious diseases and oncology, as well as animal health and food safety. The company also offers custom development services, contract manufacturing, and pharmaceutical research services such as whole genome sequencing.

Recent filings

Filing Released Lang Actions
Full year trading update
Earnings Release Classification · 100% confidence The document is a 'Full year trading update' issued by Novacyt S.A. It provides unaudited financial highlights, revenue expectations, and operational progress for the fiscal year ended December 31, 2025. It explicitly states that the full audited results will be reported later in April 2026. As this is an initial announcement of financial performance (key highlights) rather than the full annual report, it is classified as an Earnings Release (ER). FY 2025
2026-01-21 English
Résultats préliminaires pour l’année 2025
Earnings Release Classification · 100% confidence The document is titled 'Résultats préliminaires pour l'année 2025' (Preliminary results for the year 2025) and provides a summary of financial highlights, revenue figures, and operational progress for the fiscal year ending December 31, 2025. It explicitly states that these are 'non-audited' preliminary results and mentions that the full annual report will be published later in April 2026. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodic financial results containing key highlights. FY 2025
2026-01-21 French
Liquidity Agreement Monthly Update and TVR
Regulatory Filings Classification · 98% confidence The document is a monthly update regarding a liquidity agreement (share buybacks/transactions) and a disclosure of total voting rights. It details specific share purchase and sale volumes conducted by Invest Securities on behalf of the company. This falls under the category of 'Transaction in Own Shares' (POS) as it reports the company's activity in buying back its own shares through a liquidity provider.
2026-01-02 English
Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote
Transaction in Own Shares Classification · 95% confidence The document is a monthly update from Novacyt regarding its liquidity contract (share buybacks/sales) and the total number of voting rights. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Growth and AIM to inform the market about share capital changes and treasury share holdings. It does not represent a full financial report, a board change, or a major shareholding notification, but rather a routine regulatory disclosure of share activity.
2026-01-02 French
Liquidity Agreement Monthly Update and TVR
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a monthly update regarding a liquidity agreement and total voting rights for Novacyt S.A. It details share purchases and sales made by a third party (Invest Securities) under a liquidity agreement, as well as the total number of voting shares. This type of disclosure, which involves the company's own share transactions and voting rights, is classified as 'Transaction in Own Shares' (POS) as it specifically reports on the company's buyback/liquidity activity.
2025-12-01 English
Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote
Transaction in Own Shares Classification · 95% confidence The document is a monthly update from Novacyt S.A. regarding its liquidity contract (share buybacks/sales) and the total number of voting rights. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Growth and AIM to inform the market about share capital changes and treasury share holdings. It does not report a specific transaction in own shares (POS) as a standalone event, but rather a monthly summary of the liquidity contract activity and voting rights, which falls under general regulatory filings.
2025-12-01 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.